5PSQ-083 Study of the prevalence of immunogenicity in patients treated with anti-tumour necrosis factor monoclonal antibodies

BACKGROUND: The loss of response in patients treated with anti-TNFα monoclonal antibodies is relatively frequent. One of the reasons is the development of immunogenicity, causing treatment failure. PURPOSE: To determine the prevalence of immunogenicity in patients with anti-TNF monoclonal antibodies...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Candel, M Gil, Navalón, C Iniesta, Candela, M Onteniente, Redondo, L Rentero, Requejo, C Caballero, Valverde, N Salar, Muñoz, C Gallego
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 5: Patient safety and quality assurance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535275/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.437
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados